Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targets for Drug Action: Overview

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Peptide Inhibitor of Lymphocyte Activation Gene-3 Interaction with Fibrinogen-like Protein 1 Synergizes with Programmed Death-Ligand 1 Blockade to Restore T Cell Activity and Inhibit Tumor Growth.

Biomaterials research·2026

Same author

Mesothelin-Binding Peptide Inhibits Cell Migration and Enables Targeted Delivery of a Mitochondrial-Membrane-Damaging Peptide to Pancreatic Tumors.

Biomaterials research·2026

Same author

PD-L1/Lag3 Bispecific Immune Checkpoint Blocking Nanocage Exhibits Potent Antitumor Activity beyond Dual Blockade of PD-L1 and Lag3.

Biomaterials research·2026

Same author

Diabetes Belt has lower efficiency in providing diabetes preventive care than surrounding counties.

Health services & outcomes research methodology·2025

Same author

An enhancer-AAV toolbox to target and manipulate distinct interneuron subtypes.

Neuron·2025

Same author

Evaluation of Ceramic Membrane Filtration for Alternatives to Microplastics in Cosmetic Formulations Using FlowCam Analysis.

Membranes·2025

Search research articles

Related Experiment Video

Updated: Jun 4, 2026

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Nucleic acid aptamers targeting cell-surface proteins.

Pooja Dua¹, Soyoun Kim, Dong-Ki Lee

¹Global Research Laboratory for RNAi Medicine, Department of Chemistry, Sungkyunkwan University, Suwon, Republic of Korea.

Methods (San Diego, Calif.)

|February 9, 2011

Summary

Aptamers, or nucleic acid-based antibodies, are selected using SELEX technology for specific targets. These aptamers show promise as diagnostic and therapeutic agents for diseases involving cell-surface proteins.

More Related Videos

Kinetic Screening of Nuclease Activity using Nucleic Acid Probes

Kinetic Screening of Nuclease Activity using Nucleic Acid Probes

Published on: November 1, 2019

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Published on: June 23, 2011

Related Experiment Videos

Last Updated: Jun 4, 2026

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Kinetic Screening of Nuclease Activity using Nucleic Acid Probes

Kinetic Screening of Nuclease Activity using Nucleic Acid Probes

Published on: November 1, 2019

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Published on: June 23, 2011

Area of Science:

Biochemistry
Molecular Biology
Biotechnology

Background:

Aptamers are nucleic acid molecules that function as antibodies, exhibiting high affinity and specificity for their targets.
The Systematic Evolution of Ligands by EXponential enrichment (SELEX) is a key in vitro technology for aptamer identification.
SELEX has undergone numerous modifications to facilitate the selection of aptamers against challenging targets, including membrane proteins.

Purpose of the Study:

To review the SELEX process for aptamer selection targeting cell-surface proteins.
To highlight the diagnostic and therapeutic applications of aptamers generated against disease-associated membrane proteins.

Main Methods:

The review focuses on the SELEX methodology, detailing its application in identifying aptamers against cell-surface proteins.
Discussion includes variations in SELEX schemes tailored to specific protein characteristics and experimental systems.

Main Results:

Aptamers have been successfully generated for numerous disease-associated membrane proteins.
These aptamers demonstrate significant potential for both diagnostic and therapeutic applications.

Conclusions:

The SELEX process is a versatile tool for discovering aptamers that target cell-surface proteins.
Aptamers represent a promising class of reagents for advancing diagnostics and therapeutics in various diseases.